Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Genome-wide association study implicates CHRNA2 in cannabis use disorder.

Demontis D, Rajagopal VM, Thorgeirsson TE, Als TD, Grove J, Leppälä K, Gudbjartsson DF, Pallesen J, Hjorthøj C, Reginsson GW, Tyrfingsson T, Runarsdottir V, Qvist P, Christensen JH, Bybjerg-Grauholm J, Bækvad-Hansen M, Huckins LM, Stahl EA, Timmermann A, Agerbo E, Hougaard DM, Werge T, Mors O, Mortensen PB, Nordentoft M, Daly MJ, Stefansson H, Stefansson K, Nyegaard M, Børglum AD.

Nat Neurosci. 2019 Jul;22(7):1066-1074. doi: 10.1038/s41593-019-0416-1. Epub 2019 Jun 17.

PMID:
31209380
2.

Abnormal Amyloid Load in Mild Cognitive Impairment: The Effect of Reducing the PiB-PET Threshold.

Ismail R, Parbo P, Hansen KV, Schaldemose JL, Dalby RB, Tietze A, Kjeldsen PL, la Cour SH, Qvist P, Gottrup H, Eskildsen SF, Brooks DJ.

J Neuroimaging. 2019 Jul;29(4):499-505. doi: 10.1111/jon.12629. Epub 2019 May 10.

PMID:
31074062
3.

Identification of common genetic risk variants for autism spectrum disorder.

Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, Pallesen J, Agerbo E, Andreassen OA, Anney R, Awashti S, Belliveau R, Bettella F, Buxbaum JD, Bybjerg-Grauholm J, Bækvad-Hansen M, Cerrato F, Chambert K, Christensen JH, Churchhouse C, Dellenvall K, Demontis D, De Rubeis S, Devlin B, Djurovic S, Dumont AL, Goldstein JI, Hansen CS, Hauberg ME, Hollegaard MV, Hope S, Howrigan DP, Huang H, Hultman CM, Klei L, Maller J, Martin J, Martin AR, Moran JL, Nyegaard M, Nærland T, Palmer DS, Palotie A, Pedersen CB, Pedersen MG, dPoterba T, Poulsen JB, Pourcain BS, Qvist P, Rehnström K, Reichenberg A, Reichert J, Robinson EB, Roeder K, Roussos P, Saemundsen E, Sandin S, Satterstrom FK, Davey Smith G, Stefansson H, Steinberg S, Stevens CR, Sullivan PF, Turley P, Walters GB, Xu X; Autism Spectrum Disorder Working Group of the Psychiatric Genomics Consortium; BUPGEN; Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium; 23andMe Research Team, Stefansson K, Geschwind DH, Nordentoft M, Hougaard DM, Werge T, Mors O, Mortensen PB, Neale BM, Daly MJ, Børglum AD.

Nat Genet. 2019 Mar;51(3):431-444. doi: 10.1038/s41588-019-0344-8. Epub 2019 Feb 25.

4.

Brain proteome changes in female Brd1+/- mice unmask dendritic spine pathology and show enrichment for schizophrenia risk.

Paternoster V, Svanborg M, Edhager AV, Rajkumar AP, Eickhardt EA, Pallesen J, Grove J, Qvist P, Fryland T, Wegener G, Nyengaard JR, Mors O, Palmfeldt J, Børglum AD, Christensen JH.

Neurobiol Dis. 2019 Apr;124:479-488. doi: 10.1016/j.nbd.2018.12.011. Epub 2018 Dec 24.

PMID:
30590179
5.

Brain volumetric alterations accompanied with loss of striatal medium-sized spiny neurons and cortical parvalbumin expressing interneurons in Brd1+/- mice.

Qvist P, Eskildsen SF, Hansen B, Baragji M, Ringgaard S, Roovers J, Paternoster V, Molgaard S, Corydon TJ, Stødkilde-Jørgensen H, Glerup S, Mors O, Wegener G, Nyengaard JR, Børglum AD, Christensen JH.

Sci Rep. 2018 Nov 7;8(1):16486. doi: 10.1038/s41598-018-34729-5.

6.

The effect of hypoxia on ZEB1 expression in a mimetic system of the blood-brain barrier.

Leduc-Galindo D, Qvist P, Tóth AE, Fryland T, Nielsen MS, Børglum AD, Christensen JH.

Microvasc Res. 2019 Mar;122:131-135. doi: 10.1016/j.mvr.2018.08.004. Epub 2018 Aug 23.

PMID:
30144413
7.

Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression.

Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, Adams MJ, Agerbo E, Air TM, Andlauer TMF, Bacanu SA, Bækvad-Hansen M, Beekman AFT, Bigdeli TB, Binder EB, Blackwood DRH, Bryois J, Buttenschøn HN, Bybjerg-Grauholm J, Cai N, Castelao E, Christensen JH, Clarke TK, Coleman JIR, Colodro-Conde L, Couvy-Duchesne B, Craddock N, Crawford GE, Crowley CA, Dashti HS, Davies G, Deary IJ, Degenhardt F, Derks EM, Direk N, Dolan CV, Dunn EC, Eley TC, Eriksson N, Escott-Price V, Kiadeh FHF, Finucane HK, Forstner AJ, Frank J, Gaspar HA, Gill M, Giusti-Rodríguez P, Goes FS, Gordon SD, Grove J, Hall LS, Hannon E, Hansen CS, Hansen TF, Herms S, Hickie IB, Hoffmann P, Homuth G, Horn C, Hottenga JJ, Hougaard DM, Hu M, Hyde CL, Ising M, Jansen R, Jin F, Jorgenson E, Knowles JA, Kohane IS, Kraft J, Kretzschmar WW, Krogh J, Kutalik Z, Lane JM, Li Y, Li Y, Lind PA, Liu X, Lu L, MacIntyre DJ, MacKinnon DF, Maier RM, Maier W, Marchini J, Mbarek H, McGrath P, McGuffin P, Medland SE, Mehta D, Middeldorp CM, Mihailov E, Milaneschi Y, Milani L, Mill J, Mondimore FM, Montgomery GW, Mostafavi S, Mullins N, Nauck M, Ng B, Nivard MG, Nyholt DR, O'Reilly PF, Oskarsson H, Owen MJ, Painter JN, Pedersen CB, Pedersen MG, Peterson RE, Pettersson E, Peyrot WJ, Pistis G, Posthuma D, Purcell SM, Quiroz JA, Qvist P, Rice JP, Riley BP, Rivera M, Saeed Mirza S, Saxena R, Schoevers R, Schulte EC, Shen L, Shi J, Shyn SI, Sigurdsson E, Sinnamon GBC, Smit JH, Smith DJ, Stefansson H, Steinberg S, Stockmeier CA, Streit F, Strohmaier J, Tansey KE, Teismann H, Teumer A, Thompson W, Thomson PA, Thorgeirsson TE, Tian C, Traylor M, Treutlein J, Trubetskoy V, Uitterlinden AG, Umbricht D, Van der Auwera S, van Hemert AM, Viktorin A, Visscher PM, Wang Y, Webb BT, Weinsheimer SM, Wellmann J, Willemsen G, Witt SH, Wu Y, Xi HS, Yang J, Zhang F; eQTLGen; 23andMe, Arolt V, Baune BT, Berger K, Boomsma DI, Cichon S, Dannlowski U, de Geus ECJ, DePaulo JR, Domenici E, Domschke K, Esko T, Grabe HJ, Hamilton SP, Hayward C, Heath AC, Hinds DA, Kendler KS, Kloiber S, Lewis G, Li QS, Lucae S, Madden PFA, Magnusson PK, Martin NG, McIntosh AM, Metspalu A, Mors O, Mortensen PB, Müller-Myhsok B, Nordentoft M, Nöthen MM, O'Donovan MC, Paciga SA, Pedersen NL, Penninx BWJH, Perlis RH, Porteous DJ, Potash JB, Preisig M, Rietschel M, Schaefer C, Schulze TG, Smoller JW, Stefansson K, Tiemeier H, Uher R, Völzke H, Weissman MM, Werge T, Winslow AR, Lewis CM, Levinson DF, Breen G, Børglum AD, Sullivan PF; Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium.

Nat Genet. 2018 May;50(5):668-681. doi: 10.1038/s41588-018-0090-3. Epub 2018 Apr 26.

8.

Erratum: Preventive effects of kudzu root on bone loss and cartilage degradation in ovariectomized rats.

Luo Y, Zheng S, Ding Y, Dai Y, Zhou Y, Xiang R, Bay-Jensen AC, Karsdal MA, Qvist P, Zheng Q.

Am J Transl Res. 2017 Nov 15;9(11):5180. eCollection 2017.

9.

Preventive effects of kudzu root on bone loss and cartilage degradation in ovariectomized rats [corrected].

Luo Y, Zheng S, Ding Y, Dai Y, Zhou Y, Xiang R, Bay-Jensen AC, Karsdal MA, Qvist P, Zheng Q.

Am J Transl Res. 2017 Jul 15;9(7):3517-3527. eCollection 2017. Erratum in: Am J Transl Res. 2017 Nov 15;9(11):5180.

10.

Rehabilitation of Discharged Patients With Chronic Obstructive Pulmonary Disease-Are New Strategies Needed?

Morsø L, Jensen MS, von Plessen C, Qvist P.

Health Serv Res Manag Epidemiol. 2017 Jan 12;4:2333392816687704. doi: 10.1177/2333392816687704. eCollection 2017 Jan-Dec.

11.

Mice heterozygous for an inactivated allele of the schizophrenia associated Brd1 gene display selective cognitive deficits with translational relevance to schizophrenia.

Qvist P, Rajkumar AP, Redrobe JP, Nyegaard M, Christensen JH, Mors O, Wegener G, Didriksen M, Børglum AD.

Neurobiol Learn Mem. 2017 May;141:44-52. doi: 10.1016/j.nlm.2017.03.009. Epub 2017 Mar 21.

PMID:
28341151
12.

DNA Methylation Analysis of BRD1 Promoter Regions and the Schizophrenia rs138880 Risk Allele.

Dyrvig M, Qvist P, Lichota J, Larsen K, Nyegaard M, Børglum AD, Christensen JH.

PLoS One. 2017 Jan 17;12(1):e0170121. doi: 10.1371/journal.pone.0170121. eCollection 2017.

13.

The Schizophrenia-Associated BRD1 Gene Regulates Behavior, Neurotransmission, and Expression of Schizophrenia Risk Enriched Gene Sets in Mice.

Qvist P, Christensen JH, Vardya I, Rajkumar AP, Mørk A, Paternoster V, Füchtbauer EM, Pallesen J, Fryland T, Dyrvig M, Hauberg ME, Lundsberg B, Fejgin K, Nyegaard M, Jensen K, Nyengaard JR, Mors O, Didriksen M, Børglum AD.

Biol Psychiatry. 2017 Jul 1;82(1):62-76. doi: 10.1016/j.biopsych.2016.08.037. Epub 2016 Sep 15.

PMID:
27837920
14.

Cohort Profile: The Prospective Epidemiological Risk Factor (PERF) study.

Neergaard JS, Dragsbæk K, Kehlet SN, Hansen HB, Hansen G, Byrjalsen I, Alexandersen P, Lindgren LM, Bihlet AR, Riis BJ, Andersen JR, Qvist P, Karsdal MA, Christiansen C.

Int J Epidemiol. 2017 Aug 1;46(4):1104-1104i. doi: 10.1093/ije/dyw251. No abstract available.

PMID:
27789666
15.

A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D.

Henriksen K, Byrjalsen I, Andersen JR, Bihlet AR, Russo LA, Alexandersen P, Valter I, Qvist P, Lau E, Riis BJ, Christiansen C, Karsdal MA; SMC021 investigators.

Bone. 2016 Oct;91:122-9. doi: 10.1016/j.bone.2016.07.019. Epub 2016 Jul 25.

PMID:
27462009
16.

Experimental validation of methods for differential gene expression analysis and sample pooling in RNA-seq.

Rajkumar AP, Qvist P, Lazarus R, Lescai F, Ju J, Nyegaard M, Mors O, Børglum AD, Li Q, Christensen JH.

BMC Genomics. 2015 Jul 25;16:548. doi: 10.1186/s12864-015-1767-y.

17.

Aberrant recombination and repair during immunoglobulin class switching in BRCA1-deficient human B cells.

Björkman A, Qvist P, Du L, Bartish M, Zaravinos A, Georgiou K, Børglum AD, Gatti RA, Törngren T, Pan-Hammarström Q.

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2157-62. doi: 10.1073/pnas.1418947112. Epub 2015 Feb 2.

18.

[Chronic obstructive lung disease management programmes do not benefit the coordination of care pathways].

Gjersøe P, Morsø L, Jensen MS, Qvist P.

Ugeskr Laeger. 2014 Sep 29;176(40). pii: V04140244. Danish.

PMID:
25294515
19.

Biomarkers of cartilage and surrounding joint tissue.

Siebuhr AS, He Y, Gudmann NS, Gram A, Kjelgaard-Petersen CF, Qvist P, Karsdal MA, Bay-Jensen AC.

Biomark Med. 2014;8(5):713-31. doi: 10.2217/bmm.13.144. Review.

PMID:
25123039
20.

Analysis of t(9;17)(q33.2;q25.3) chromosomal breakpoint regions and genetic association reveals novel candidate genes for bipolar disorder.

Rajkumar AP, Christensen JH, Mattheisen M, Jacobsen I, Bache I, Pallesen J, Grove J, Qvist P, McQuillin A, Gurling HM, Tümer Z, Mors O, Børglum AD.

Bipolar Disord. 2015 Mar;17(2):205-11. doi: 10.1111/bdi.12239. Epub 2014 Jul 23.

PMID:
25053281
21.

Role of hormones in cartilage and joint metabolism: understanding an unhealthy metabolic phenotype in osteoarthritis.

Bay-Jensen AC, Slagboom E, Chen-An P, Alexandersen P, Qvist P, Christiansen C, Meulenbelt I, Karsdal MA.

Menopause. 2013 May;20(5):578-86. doi: 10.1097/GME.0b013e3182745993. Review.

PMID:
23615651
22.

Molecular serum and urine marker repertoire supporting clinical research on joint diseases.

Qvist P, Bay-Jensen AC, Christiansen C, Sondergaard BC, Karsdal MA.

Best Pract Res Clin Rheumatol. 2011 Dec;25(6):859-72. doi: 10.1016/j.berh.2011.11.004. Review.

PMID:
22265266
23.

CtIP Mutations Cause Seckel and Jawad Syndromes.

Qvist P, Huertas P, Jimeno S, Nyegaard M, Hassan MJ, Jackson SP, Børglum AD.

PLoS Genet. 2011 Oct;7(10):e1002310. doi: 10.1371/journal.pgen.1002310. Epub 2011 Oct 6.

24.

A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M).

Leeming Dj, He Y, Veidal S, Nguyen Q, Larsen D, Koizumi M, Segovia-Silvestre T, Zhang C, Zheng Q, Sun S, Cao Y, Barkholt V, Hägglund P, Bay-Jensen A, Qvist P, Karsdal M.

Biomarkers. 2011 Nov;16(7):616-28. doi: 10.3109/1354750X.2011.620628. Epub 2011 Oct 11.

PMID:
21988680
25.

Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities.

Karsdal MA, Woodworth T, Henriksen K, Maksymowych WP, Genant H, Vergnaud P, Christiansen C, Schubert T, Qvist P, Schett G, Platt A, Bay-Jensen AC.

Arthritis Res Ther. 2011 Apr 28;13(2):215. doi: 10.1186/ar3280. Review.

26.

Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy.

Henriksen K, Byrjalsen I, Qvist P, Beck-Nielsen H, Hansen G, Riis BJ, Perrild H, Svendsen OL, Gram J, Karsdal MA, Christiansen C; BALLET Trial Investigators.

Diabetes Metab Res Rev. 2011 May;27(4):392-401. doi: 10.1002/dmrr.1187.

PMID:
21328517
27.

Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM--increased serum CIIM in subjects with severe radiographic osteoarthritis.

Bay-Jensen AC, Liu Q, Byrjalsen I, Li Y, Wang J, Pedersen C, Leeming DJ, Dam EB, Zheng Q, Qvist P, Karsdal MA.

Clin Biochem. 2011 Apr;44(5-6):423-9. doi: 10.1016/j.clinbiochem.2011.01.001. Epub 2011 Jan 9.

PMID:
21223960
28.

Serum N-Terminal Propeptide of Collagen Type I is Associated with the Number of Bone Metastases in Breast and Prostate Cancer and Correlates to Other Bone Related Markers.

Leeming DJ, Koizumi M, Qvist P, Barkholt V, Zhang C, Henriksen K, Byrjalsen I, Karsdal MA.

Biomark Cancer. 2011 Mar 3;3:15-23. doi: 10.4137/BIC.S6484. eCollection 2011.

29.

Enzyme-linked immunosorbent serum assays (ELISAs) for rat and human N-terminal pro-peptide of collagen type I (PINP)--assessment of corresponding epitopes.

Leeming DJ, Larsen DV, Zhang C, Hi Y, Veidal SS, Nielsen RH, Henriksen K, Zheng Q, Barkholt V, Riis BJ, Byrjalsen I, Qvist P, Karsdal MA.

Clin Biochem. 2010 Oct;43(15):1249-56. doi: 10.1016/j.clinbiochem.2010.07.025. Epub 2010 Aug 13.

PMID:
20709044
30.

Matrix metalloproteinase-9-mediated type III collagen degradation as a novel serological biochemical marker for liver fibrogenesis.

Veidal SS, Vassiliadis E, Barascuk N, Zhang C, Segovia-Silvestre T, Klickstein L, Larsen MR, Qvist P, Christiansen C, Vainer B, Karsdal MA.

Liver Int. 2010 Oct;30(9):1293-304. doi: 10.1111/j.1478-3231.2010.02309.x.

PMID:
20666994
31.

Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials.

Karsdal MA, Henriksen K, Bay-Jensen AC, Molloy B, Arnold M, John MR, Byrjalsen I, Azria M, Riis BJ, Qvist P, Christiansen C.

J Clin Pharmacol. 2011 Apr;51(4):460-71. doi: 10.1177/0091270010372625. Epub 2010 Jul 21. Review.

PMID:
20660294
32.

[The case manager--from words to deeds?].

Lindegaard BR, Qvist P.

Ugeskr Laeger. 2010 Apr 19;172(16):1197-200. Danish.

PMID:
20423661
33.

Application of biochemical markers in development of drugs for treatment of osteoarthritis.

Qvist P, Christiansen C, Karsdal MA, Madsen SH, Sondergaard BC, Bay-Jensen AC.

Biomarkers. 2010 Feb;15(1):1-19. doi: 10.3109/13547500903295873. Review.

PMID:
20085489
34.

Aggrecanase- and matrix metalloproteinase-mediated aggrecan degradation is associated with different molecular characteristics of aggrecan and separated in time ex vivo.

Madsen SH, Sumer EU, Bay-Jensen AC, Sondergaard BC, Qvist P, Karsdal MA.

Biomarkers. 2010 May;15(3):266-76. doi: 10.3109/13547500903521810.

PMID:
20039789
35.

Suppression of MMP activity in bovine cartilage explants cultures has little if any effect on the release of aggrecanase-derived aggrecan fragments.

Wang B, Chen P, Jensen AC, Karsdal MA, Madsen SH, Sondergaard BC, Zheng Q, Qvist P.

BMC Res Notes. 2009 Dec 18;2:259. doi: 10.1186/1756-0500-2-259.

36.

Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis?

Bay-Jensen AC, Hoegh-Madsen S, Dam E, Henriksen K, Sondergaard BC, Pastoureau P, Qvist P, Karsdal MA.

Rheumatol Int. 2010 Feb;30(4):435-42. doi: 10.1007/s00296-009-1183-1. Epub 2009 Oct 9. Review.

PMID:
19816688
37.

Biochemical markers of joint tissue turnover.

Bay-Jensen AC, Sondergaard BC, Christiansen C, Karsdal MA, Madsen SH, Qvist P.

Assay Drug Dev Technol. 2010 Feb;8(1):118-24. doi: 10.1089/adt.2009.0199. Review.

PMID:
19715454
38.

Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development.

Karsdal MA, Henriksen K, Leeming DJ, Mitchell P, Duffin K, Barascuk N, Klickstein L, Aggarwal P, Nemirovskiy O, Byrjalsen I, Qvist P, Bay-Jensen AC, Dam EB, Madsen SH, Christiansen C.

Biomarkers. 2009 May;14(3):181-202. doi: 10.1080/13547500902777608. Review.

PMID:
19399662
39.

Selective monitoring of vitamin D2 and D3 supplementation with a highly specific 25-hydroxyvitamin D3 immunoassay with negligible cross-reactivity to 25-hydroxyvitamin D2.

Li B, Byrjalsen I, Glendenning P, Henriksen DB, Hoeck HC, Taranto M, Vasikaran S, Fraser WD, Christiansen C, Qvist P.

Clin Chim Acta. 2009 Jun 27;404(2):144-8. doi: 10.1016/j.cca.2009.03.043. Epub 2009 Mar 29.

PMID:
19336231
40.

Is bone quality associated with collagen age?

Leeming DJ, Henriksen K, Byrjalsen I, Qvist P, Madsen SH, Garnero P, Karsdal MA.

Osteoporos Int. 2009 Sep;20(9):1461-70. doi: 10.1007/s00198-009-0904-3. Epub 2009 Mar 28. Review.

PMID:
19330423
41.

Changes in 25-Hydroxyvitamin D3 to oral treatment with vitamin D3 in postmenopausal females with osteoporosis.

Hoeck HC, Li B, Qvist P.

Osteoporos Int. 2009 Aug;20(8):1329-35. doi: 10.1007/s00198-008-0790-0. Epub 2008 Dec 13.

PMID:
19083075
42.

[Risk stratification of patients with diabetes mellitus].

Qvist P, Glintborg D, Andries A, Hansen C.

Ugeskr Laeger. 2008 Oct 6;170(41):3235-8. Danish.

PMID:
18940155
43.

Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI.

Dam EB, Byrjalsen I, Karsdal MA, Qvist P, Christiansen C.

Osteoarthritis Cartilage. 2009 Mar;17(3):384-9. doi: 10.1016/j.joca.2008.07.009. Epub 2008 Sep 3.

44.

The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon?

Qvist P, Bay-Jensen AC, Christiansen C, Dam EB, Pastoureau P, Karsdal MA.

Pharmacol Res. 2008 Jul;58(1):1-7. doi: 10.1016/j.phrs.2008.06.001. Epub 2008 Jun 8. Review.

PMID:
18590824
45.

Does increased local bone resorption secondary to breast and prostate cancer result in increased cartilage degradation?

Leeming DJ, Byrjalsen I, Qvist P, Koizumi M, Lynnerup N, Fregerslev M, Sørensen MG, Christiansen C, Karsdal MA.

BMC Cancer. 2008 Jun 27;8:180. doi: 10.1186/1471-2407-8-180.

46.

Patients with rheumatoid arthritis have an altered circulatory aggrecan profile.

Rousseau JC, Sumer EU, Hein G, Sondergaard BC, Madsen SH, Pedersen C, Neumann T, Mueller A, Qvist P, Delmas P, Karsdal MA.

BMC Musculoskelet Disord. 2008 May 28;9:74. doi: 10.1186/1471-2474-9-74.

47.

[Multifactorial organization of diabetic care].

Rytter L, Borch-Johnsen K, Qvist P.

Ugeskr Laeger. 2008 May 19;170(21):1803. Danish. No abstract available.

PMID:
18492444
48.

Biochemical markers for monitoring response to therapy: evidence for higher bone specificity by a novel marker compared with routine markers.

Leeming DJ, Hegele A, Byrjalsen I, Hofmann R, Qvist P, Karsdal MA, Schrader AJ, Wagner R, Olbert P.

Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1269-76. doi: 10.1158/1055-9965.EPI-07-2697.

49.

Evaluation of cartilage and bone degradation in a murine collagen antibody-induced arthritis model.

Oestergaard S, Rasmussen KE, Doyle N, Varela A, Chouinard L, Smith SY, Qvist P, Karsdal MA.

Scand J Immunol. 2008 Mar;67(3):304-12. doi: 10.1111/j.1365-3083.2007.02060.x.

50.

Evaluation of cartilage damage by measuring collagen degradation products in joint extracts in a traumatic model of osteoarthritis.

Nielsen RH, Stoop R, Leeming DJ, Stolina M, Qvist P, Christiansen C, Karsdal MA.

Biomarkers. 2008 Feb;13(1):79-87.

PMID:
17852072

Supplemental Content

Support Center